Omar Obeidat, Mohamed F Ismail, Saeed Abughazaleh, Hashim Al-Ani, Mohammad Tarawneh, Laith Alhuneafat, Ali Obeidat, Abedallah Obeidat, Qusai Alqudah, Moh'd Alamin Daise, Hamza Alzghoul, Mohammad Al-Hammouri, Ward Althunibat, Ann Tong, Mazahir Alimohamed
{"title":"Decoding the evidence: A synopsis of indications and evidence for catheter ablation in atrial fibrillation (Review).","authors":"Omar Obeidat, Mohamed F Ismail, Saeed Abughazaleh, Hashim Al-Ani, Mohammad Tarawneh, Laith Alhuneafat, Ali Obeidat, Abedallah Obeidat, Qusai Alqudah, Moh'd Alamin Daise, Hamza Alzghoul, Mohammad Al-Hammouri, Ward Althunibat, Ann Tong, Mazahir Alimohamed","doi":"10.3892/mi.2024.200","DOIUrl":null,"url":null,"abstract":"<p><p>The present study reviews the role of catheter ablation (CA) in the management of atrial fibrillation (AF), a widespread arrhythmia associated with increased morbidity and mortality. The present review explores current indications and recent evidence supporting CA, assessing patient outcomes and identifying common complications associated with the procedure. Emphasis is placed on optimizing risk factors prior to ablation, including weight control and hypertension management, as these measures can significantly enhance post-procedural outcomes. The present review also discusses the use of antiarrhythmic and anticoagulant therapies following CA to minimize recurrence and reduce stroke risk. Additionally, the cost-effectiveness of CA is discussed, comparing its long-term economic impact with that of medical therapy alone. The present comprehensive review provides insight into best practices for AF management, supporting CA as a promising approach when integrated with targeted lifestyle modifications and pharmacological support for improved, patient-centered outcomes.</p>","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"5 1","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571048/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine international","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/mi.2024.200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The present study reviews the role of catheter ablation (CA) in the management of atrial fibrillation (AF), a widespread arrhythmia associated with increased morbidity and mortality. The present review explores current indications and recent evidence supporting CA, assessing patient outcomes and identifying common complications associated with the procedure. Emphasis is placed on optimizing risk factors prior to ablation, including weight control and hypertension management, as these measures can significantly enhance post-procedural outcomes. The present review also discusses the use of antiarrhythmic and anticoagulant therapies following CA to minimize recurrence and reduce stroke risk. Additionally, the cost-effectiveness of CA is discussed, comparing its long-term economic impact with that of medical therapy alone. The present comprehensive review provides insight into best practices for AF management, supporting CA as a promising approach when integrated with targeted lifestyle modifications and pharmacological support for improved, patient-centered outcomes.
心房颤动是一种广泛存在的心律失常,与发病率和死亡率的增加有关,本研究回顾了导管消融术(CA)在心房颤动治疗中的作用。本综述探讨了当前的适应症和支持 CA 的最新证据,评估了患者的治疗效果,并确定了与手术相关的常见并发症。重点在于消融术前优化风险因素,包括控制体重和高血压,因为这些措施可显著提高术后疗效。本综述还讨论了 CA 术后抗心律失常和抗凝疗法的使用,以尽量减少复发和降低中风风险。此外,本综述还讨论了 CA 的成本效益,比较了 CA 与单纯药物治疗的长期经济影响。本综述深入探讨了房颤管理的最佳实践,支持将 CA 与有针对性的生活方式调整和药物支持相结合,以改善以患者为中心的疗效,将 CA 作为一种很有前景的方法。